Iptacopan : First Approval
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal complement-mediated intravascular haemolysis and complement 3-mediated extravascular haemolysis. On 5 December 2023, iptacopan received approval in the USA for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH). This article summarizes the milestones in the development of iptacopan leading to this first approval for PNH.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Drugs - (2024) vom: 22. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Syed, Yahiya Y [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 22.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1007/s40265-024-02009-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370072286 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370072286 | ||
003 | DE-627 | ||
005 | 20240323235915.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240323s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40265-024-02009-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1343.xml |
035 | |a (DE-627)NLM370072286 | ||
035 | |a (NLM)38517653 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Syed, Yahiya Y |e verfasserin |4 aut | |
245 | 1 | 0 | |a Iptacopan |b First Approval |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 22.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
520 | |a Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal complement-mediated intravascular haemolysis and complement 3-mediated extravascular haemolysis. On 5 December 2023, iptacopan received approval in the USA for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH). This article summarizes the milestones in the development of iptacopan leading to this first approval for PNH | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
773 | 0 | 8 | |i Enthalten in |t Drugs |d 1976 |g (2024) vom: 22. März |w (DE-627)NLM00001611X |x 1179-1950 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40265-024-02009-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 22 |c 03 |